Retatrutide primarily operates on a systemic, hormonal level, influencing appetite, satiety, and glucose regulation through its triple agonism of GIP, GLP-1, and glucagon receptors
It also fights damage from free radicals, making it a strong antioxidant
For example, after a median observation time of 2.1 years in the SUSTAIN 6 clinical trial, once-weekly semaglutide was shown to significantly reduce the rate of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death in patients with T2D who were at high cardiovascular risk [9]
APOE genotype-dependent modulation of astrocyte chemokine CCL3 production
These medications mimic a natural hormone (GLP-1) that helps control appetite (food noise), slow digestion/ constipation, and promote fullness , making it easier to manage caloric intake and lose weight safely
This needs more research, but its another point in tirzepatides column for patients worried about losing muscle along with fat
